DKF 361
Alternative Names: DKF-361Latest Information Update: 18 Mar 2021
At a glance
- Originator Dongkook Pharmaceutical
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Hypertension
Most Recent Events
- 09 Mar 2021 Preclinical trials in Hypertension in South Korea (unspecified route) before March 2021 (Dongkook pharmaceuticals pipeline, March 2021)